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Abstract
Background: Although synovial sarcoma is the 3rd most commonly occurring mesenchymal tumor in young adults,
usually with a highly aggressive clinical course; remarkable differences can be seen regarding the clinical outcome.
According to comparative genomic hybridization (CGH) data published in the literature, the simple and complex
karyotypes show a correlation between the prognosis and clinical outcome. In addition, the connection between
DNA ploidy and clinical course is controversial. The aim of this study was using a fine-tuning interpretation of our
DNA ploidy results and to compare these with metaphase high-resolution CGH (HR-CGH) results.
Methods: DNA ploidy was determined on Feulgen-stained smears in 56 synovial sarcoma cases by image cytometry;
follow up was available in 46 cases (average: 78 months). In 9 cases HR-CGH analysis was also available.
Results: 10 cases were found DNA-aneuploid, 46 were DNA-diploid by image cytometry. With fine-tuning of the
diploid cases according to the 5c exceeding events (single cell aneuploidy), 33 cases were so called “simple-diploid”
(without 5c exceeding events) and 13 cases were “complex-diploid"; containing 5c exceeding events (any number).
Aneuploid tumors contained large numbers of genetic alterations with the sum gain of at least 2 chromosomes (A-,
B- or C-group) detected by HR-CGH. In the “simple-diploid” cases no or few genetic alterations could be detected,
whereas the “complex-diploid” samples numerous aberrations (equal or more than 3) could be found.
Conclusions: Our results show a correlation between the DNA-ploidy, a fine-tuned DNA-ploidy and the HR-CGH
results. Furthermore, we found significant correlation between the different ploidy groups and the clinical outcome
(p < 0.05).
Keywords: High-Resolution Comparative Genomic Hybridization, HR-CGH, synovial sarcoma, DNA ploidy, clinical
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Background
Synovial sarcoma (SS) is the 3rd most common mesench-
ymal spindle cell tumor [1]. It occurs most commonly in
the young, representing about 8% of all soft tissue sarco-
mas but about 15-20% of cases in adolescents and young
adults [2]. The peak of incidence is before the 4th decade
and males are affected more often than females (ratio
around 1.2:1). Almost all SSs are high-grade lesions with
a 5-year overall survival rate of 36-76%, depending on the
patient’s age, the tumor size, the proportion of poorly
differentiated areas and the resectability of the tumor.
Histologically, two distinct subtypes can be distinguished:
a monophasic, containing spindle cells; and a biphasic,
containing both an epithelial and a spindle cell compo-
nent [3]. A rare form of monophasic SS also exists, con-
taining only epithelial-like cells [4]. The monophasic
subtype is more common than the biphasic one. SS has a
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somes × and 18, t(X;18) (p11.2;q11.2), represented in
more than 95% of the cases. The translocation fuses the
SYT gene from chromosome 18 to either of three highly
homologous genes at Xp11: SSX1, SSX2 or SSSX4. SYT-
SSX1, SYT-SSX2 and SYT-SSX4 are thought to function
as transcriptional regulators [5]. It has been shown that
the type of fusion transcript most probably correlates
with the clinical outcome and HER-2 oncogene amplifi-
cation is associated with a lower risk of developing
metastasis [6-8]. According to the comparative genomic
hybridization (CGH) data published in the literature,
simple and complex karyotypes show correlation with
the prognosis [9,10], whereas the connection between
DNA ploidy and clinical course is controversial [11]. For
this reason, we performed a fine-tuned interpretation of
our DNA ploidy results and compared these to high-
resolution comparative genomic hybridization (HR-
CGH) outcome, by using the same samples. We also
examined, whether there is an association between the
ploidy status and the metastasis or recurrence of the
tumor.
Methods
Tumor samples
56 synovial sarcoma cases were selected for this study.
All cases were classified according to the World Health
Organization (WHO) classification of tumors of soft tis-
sue [1]. In the specimens selected for CGH analysis, the
proportion of tumor cells were estimated after hematoxy-
lin-eosin staining of tissue sections preceding to DNA
extraction. In all cases the tumor cells comprised at least
85% of the total tissue areas. One part of the surgically
resected tumor tissues were frozen at -80°C. The other
parts of the tumors were in formalin-fixed and paraffin-
embedded status. Furthermore, in some cases fresh-made
smears were available. Follow up was available in 46
cases (average: 78 months) with an interval of 38 to 92
months. The clinical data of patients are summarized in
Table 1. All patients’ information was coded, with com-
plete clinical data available only for physicians involved
in the treatment of these patients. This study was
approved by the ethics committee of the Semmelweis
University (approval number: 230-151/2006-1018EKU),
and all patients gave their informed consent.
DNA smear image cytometry/DNA image analysis
The DNA smear image cytometry was performed on 56
synovial sarcoma cases. The fresh-made smears were
ready to use, the deep-frozen and the formalin-fixed and
paraffin-embedded tissue samples needed preceding pre-
parations. Single-cell layer smears were prepared on
glass slides from the frozen tissue samples. The fresh-
made and single-cell layer smears were post-fixed in 4%
Table 1 Clinical data and result of DNA content analysis
of 56 patients with synovial sarcoma
No. Sex Age (Years) Diagnosis DI Histogram Follow-up
1 M 41 MSS 1.15 A M
2 M 33 PSS 1.21 A M(D)
3 F 63 MSS 1.08 Dc M
4 F 48 MSS 0.96 Dc N
5 F 38 BSS 0.96 Dc R
6 F 28 BSS 0.93 Ds N
7 M 13 MSS 1.07 Ds N
8 M 25 MSS 0.95 Ds M
9 M 55 PSS 1 Ds N
10 F 22 MSS 0.95 Ds M
11 F 47 MSS 0.91 Ds M
12 M 22 MSS 1.01 Ds M(D)
13 M 39 MSS 1.06 Ds M(D)
14 M 67 BSS 0.96 Ds R
15 F 52 MSS 0.92 Ds M
16 M 31 MSS 0.93 Ds N
17 F 11 BSS 0.97 Ds M(D)
18 F 41 MSS 1 Ds R
19 F 42 MSS 0.98 Ds M(D)
20 M 48 MSS 0.96 Ds M
21 F 62 MSS 0.93 Ds M
22 F 20 MSS 1.05 Ds M
23 M 22 MSS 1.04 Ds N
24 M 56 BSS 0.98 Ds R
25 F 13 BSS 0.95 Ds N
26 M 43 MSS/PSS 0.94 Ds R
27 F 58 MSS 0.9 Ds M
28 M 36 MSS 1.09 Ds R
29 M 41 MSS 0.92 Ds R
30 M 43 MSS 0.97 Ds R
31 F 32 BSS 0.99 Ds N
32 F 68 MSS 0.99 Ds N
33 F 68 MSS 1.64 A M
34 F 29 MSS 1.85 A M
35 F 21 PSS 1.17 A M
36 F 58 PSS 1.51 A M
37 M 37 MSS/PSS 1.6 A M
38 M 60 MSS 1.26 A M
39 M 58 PSS 1.34 A M
40 F 31 MSS 1.19 A M(D)
41 M 42 MSS 1 Dc M(D)
42 F 29 MSS 1.08 Dc M
43 M 37 PSS 1.07 Dc M
44 M 46 MSS 1.04 Dc N
45 M 34 PSS 1.03 Dc M
46 F 32 MSS 0.95 Dc R
47 M 23 BSS 0.95 Ds ND
48 M 52 MSS 1.02 Ds ND
49 M 14 BSS 0.95 Ds ND
50 M 42 PSS 0.92 Ds ND
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Page 2 of 7buffered formalin for 30 min. From the formalin-fixed
and paraffin-embedded samples the nuclei were isolated
before the smears were prepared. Three 50 μm sections
were cut from each paraffin block. The sections were
deparaffinized in xylene and rehydrated in a series of
decreasing concentration of ethanol. The tissue was
digested in Carlsberg’s solution (0, 1% Sigma protease
XXIV; 0, 1 M Tris buffer; 0, 07M NaCl; pH 7, 2) for 45
min at 37°C in thermomixer. After filtration the nuclear
extract was washed in distilled water, the nuclei were
fixed in 70% ethanol and dropped on glass slide to pre-
pare smear.
The nuclear DNA content was analyzed by DNA image
cytometry, based on adsorption technique. In order to
make the nuclear extract suitable for quantitative analysis
we stained the samples by a stoichiometric method
according to Feulgen using Schiff reagent (Merck, Darm-
stadt, Germany). Sample preparation, fixation and staining
were performed according to the consensus report of the
ESAP task force on the standardization of diagnostic DNA
image cytometry [12]. DNA image data processing was
carried out using a regular microscope with an image-sen-
sing scanner, interfaced to a regular PC with dedicated
software installed (CYDOK R, Fa., Hilgers, Königswinter,
Germany). We used a 40x objective and an interference
filter (565 ± 10nm). At least 200 diagnostic cells were ana-
lyzed on each smears. The integrated optical density
(IOD) of Feulgen-stained reference cells (e.g. lymphocytes
or granulocytes) were used as an internal standard for the
normal diploid DNA content (2c) to rescale the IOD
values into c-values. The coefficient of variation of the
reference cells was between 3% and 5%. The reference
cells were non tumor cells found in the samples. Having
measured 30 reference cells and 200 tumor cells, image
analysis histograms were generated. A DNA index (DI) 1
corresponds to the 2c diploid DNA content and the DI of
2.5 to the 5c DNA content. Between DI of 0.9-1.1 the sam-
ple is considered to be diploid. Outside of this range the
tumor is considered to be aneuploid. To define DNA-
aneuploidy we used the stem line interpretation of
Haroske et al. [12]. Single cell aneuploidy (complex diploid
tumor) was defined as the tumor had a diploid stemline
but we found any cell among 5c exceeding events -
excluding eusomic polysomy (8c +/- 0.4c) - the case was
considered as complex diploid. [13]
Metaphase high-resolution comparative genomic
hybridization (HR-CGH)
A l lo ft h e9c a s e so fs y n o v i a ls a r c o m a ,f r o mw h i c hf r e s h
frozen tissue samples were available, HR-CGH analysis
was performed. DNA was extracted with a standard salting
out method according to Miller et al. [14]. Hybridization
was performed according to a standard procedure [15].
Briefly, sex-matched normal and tumor DNAs were
labeled with SpectrumRed-dUTP and SpectrumGreen-
dUTP, respectively by nick translation using a commercial
kit (Vysis, Downers Grove, IL, USA). Hybridization was
performed in a moist chamber at 37°C for 3 days in the
presence of an access of blocking Human Cot-1 DNA
(Vysis). The metaphases were captured with epifluores-
cence microscope (Nikon Eclipse E600) equipped with a
monochrome CCD camera, and were analyzed using
LUCIA CGH-Advanced Statistics 1.5.0 software (Labora-
tory Imaging Ltd, Prague, Czech Republic). At least 15
karyotypes were analyzed in each case. Ratio profiles were
evaluated by dynamic Standard Reference Interval based
on an average of 15 normal CGH analyses using 16 nor-
mal DNAs instead of conventionally fixed thresholds. The
gains and losses were detected by comparing the 99.5%
confidence interval of the mean ratio profiles of the test
samples to the 99.5% dynamic standard reference interval
[16]. We have applied the correction for unreliable hybri-
dizations function to improve the specificity of genomic
gains and losses detection. Negative and positive controls
were included in each experiment. Two differentially
labeled DNAs (normal test and normal reference) hybri-
dized together served as a negative control. Positive con-
trol was created from the specimens with a known
trisomy 21, and partial deletion of chromosome 17, del
(17)(p13). Heterochromatic regions in the centromeric
and paracentromeric areas of the chromosomes, the short
arm of the acrocentric chromosomes, and the Y hetero-
chromatic as well as telomeric regions were not included
in the evaluation.
Statistics
For statistical analysis the Fisher’se x a c tt e s tw a su s e d .
Differences were considered statistically significant when
P value was < 0.05.
Results
10 cases (17.9%) were aneuploid by image cytometry,
the average DI was 1.40 (Figure 1). The histogram of 46
neoplasms (82.1%) represented diploid tumor with 0.99
Table 1 Clinical data and result of DNA content analysis
of 56 patients with synovial sarcoma (Continued)
51 F 56 MSS 1.03 Ds ND
52 F 25 BSS 1.02 Ds ND
53 M 32 MSS 0.95 Dc ND
54 F 23 PSS 0.94 Dc ND
55 M 24 BSS 1.03 Dc ND
56 F 70 PSS 1.06 Dc ND
Abbreviations: DI, DNA index; MSS, monophasic synovial sarcoma; BSS,
biphasic synovial sarcoma; PSS, poorly differentiated synovial sarcoma; M,
metastasis; R, only recurrence; M(D), died because of tumor; N, no recurrence
and no metastasis; ND, no data; A, aneuploid; Ds, diploid simple (diploid
stemline without 5c exceeding events); Dc, diploid complex (diploid stemline
with any cell of 5c exceeding events)
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cases according to the 5c exceeding events which repre-
sent single cell aneuploidy. 33 cases (71.7% of diploid
cases) without 5c exceeding events were considered
“simple-diploid” (Figure 2) and 13 cases (28.3% of
diploid cases) fell into the “complex-diploid” group con-
taining any 5c exceeding events (Figure 3). These results
are shown in Table 1. Regarding the cases having been
followed-up we had 10 aneuploid, 9 complex-diploid
and 27 simple-diploid synovial sarcomas.
Only aberrations that are present in a high proportion
of tumor cells can be detected by CGH. If the normal
cell content is more than 50% of the tumor specimen,
the evaluation becomes difficult. The average tumor cell
concentration in this material was 85%. This evaluation
and selection of representative tumor material is extre-
mely important for the outcome of CGH.
HR-CGH analysis revealed chromosome imbalances in 5
out of the 9 (55.5%) SSs; in 4 cases neither chromosomal
gains nor losses were found. The chromosomal imbalances
found are listed in Table 2. Aneuploid tumors contained a
large number of genetic alterations with the sum gain of at
least 2 chromosomes (A-, B- or C-group). These single
alterations consisted of gains of chromosome were 1p, 1q,
2q24-q37, 5, 7q11.2-q36, 8, 8q23-24, 9p, 12p13-q22 and
15q22-26 and losses of chromosome were 3p14-p26, 4,
5p14, 12q23-24, 13q12-q22, 15q11.2-21, 16q and 18q12-
q22 (Figure 1). The “complex-diploid” samples showed
Figure 1 DNA histogram (a) and HR-CGH ideogram (b) of
aneuploid synovial sarcoma (case 2). Aneuploid tumor with a
complex gain (1q, +5, +8, 9p, 12p13-q22, 15q22-26) and loss
(12q23-24, 15q11.2-21) of DNA content. DNA index was found to be
1.21. The lines at the right of the chromosome ideogram represent
DNA gains, lines at the left, DNA losses.
Figure 2 DNA histogram (a) and HR-CGH ideogram (b) of a simple
diploid synovial sarcoma (case 8). Note there is no cell above the 5c
value and there is no alteration concerning the CGH results.
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of chromosome 3q, 4 and 9, and losses of chromosome
1p12-22, 3p, 4q28-q35, 5q15-35, 6q12-q23, 16q, 19, 20 and
22 (Figure 3). In “simple-diploid” cases no genetic altera-
tions could be detected by HR-CGH (Figure 2).
Concerning the clinical course, 8 out of 10 patients
(80%) with aneuploid tumor had metastasis and 2 (20%)
died of disease. Out of 27 patients with “simple-diploid”
tumor, 8 patients (29.6%) had metastasis, 7 (25.9%) had
recurrence, 4 (14.8%) died of disease and 8 (29.6%) are
tumor-free. 4 of 9 patients (44.4%) with “complex-
diploid” tumor had metastasis, 2 (22.2%) had recurrence,
1 (11.1%) died of disease and 2 (22.2%) had no recurrent
tumor (Table 1). Using Fisher’s exact test the three
groups proved to be significantly different (P = 0.04)
(Table 3).
Discussion
The treatment of SSs is still an unsolved issue. Although
the specific chromosomal translocation characteristic to
SSs and its outcome, the chimeric protein is well-known,
appropriate targeted therapy could not be found. Its pos-
sible cause could be that the specific translocation is
essential for the initiation of tumorgenesis, but in tumor
progression (recurrence and metastasis) further genetic
alterations also play a crucial role. Since these genetic
alterations arise randomly (typical losses and gains of
chromosomes or chromosomal segments are not known)
[9,10], measurement of the total DNA content gains high
importance in estimating the prognosis of the disease
and accordingly, in the selection of the aggressiveness of
the therapy. A current report of a biphasic SS case with
genomic instability revealed great cytogenetic heteroge-
neity within chromosome numbers and the recurrent
presence of dicentric chromosomes [17]. Nevertheless,
whether and how the biological behavior of the tumor is
affected by cytogenetic changes remains uncertain.
Some SSs recur or develop metastases after a long time,
sometimes 5-10 years after the primary diagnosis while
others are more aggressive. This can only be partly
Figure 3 DNA histogram (a) and HR-CGH ideogram (b) of a
complex diploid synovial sarcoma (case 3). Though the tumor is
diploid, 8 cells proved to be above the 5c value. CGH revealed the
gain of the whole chromosomes of 4 and 9. The lines at the right
of the chromosome ideogram represent DNA gains.
Table 2 High-resolution comparative genomic hybridization(HR-CGH) data of 9 synovial sarcoma patients
No. Histogram Gain Loss
1 A 1p, 2q24-q37, 7q11.2-q36, +8, 8q23-24 3p14-p26, -4, 5p14, 13q12-q22, 16q, 18q12-q22
2 A 1q, +5, +8, 9p, 12p13-q22, 15q22-26 12q23-24, 15q11.2-21
3 Dc +4, +9 -
4 Dc 3q 1p12-22, 3p, 5q15-35, -19, -20, -22
5 Dc - 4q28-q35, 6q12-q23, 16q
6D s - -
7D s - -
8D s - -
9D s - -
Abbreviations: A, aneuploid; Dc, diploid-complex; Ds, diploid-simple
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age, tumor size, extent of poorly differentiated areas and
the resectability of the tumor). Karyotyping and CGH
analyses provide excellent insight into the sum genetic
alterations of the tumor, but they are considerably time
consuming and expensive methods. Measurement of the
sum DNA content by flow or image cytometry can be
faster, easier and cheaper to perform. The aim of the
study was to observe whether the frequently occurring
diploid SSs could be divided into further subgroups
which show correlation to simple or complex karyotype.
Although CGH is a screening method for DNA copy
number changes of the entire genome, it only detects
“average” genetic abnormalities of the tumor specimen.
Furthermore, only aberrations involving losses or gains of
DNA sequences can be detected, whereas balanced chro-
mosome abnormalities, such as reciprocal translocations,
inversions, and point mutations are not detectable [18].
CGH cannot recognize changes if the fraction of normal
cells is high or if cells are polyploid. Therefore, normal
findings may be false negative. The samples in our popula-
tion contained high fraction (at least 85%) of tumor cells.
We observed in our samples the most frequent chromo-
some alterations described in SS: gain of chromosome 2,
8, 12p, 12q and loss in 3p14 [9,10]. The most likely candi-
date genes at 12q13-12q15 are MDM2, CDK2, ERBB3,
SAS and CDK4; and RASSF1 at 3p21.3. A clear association
was described between gain of SAS and poor prognosis
[10].
Our results show a correlation between DNA-ploidy,
fine-tuned DNA-ploidy and the HR-CGH results. Diploid
complex cases show numerous genetic alterations
whereas in diploid simple cases no detectable chromo-
some aberrations were found. The explanation of this
phenomenon is not evident: the complex diploid tumors
cannot be regarded as aneuploid, even if the complex
karyotype shows evident aneuploidy (although at a more
sensitive level). It may be explained as individual cells
with 5c exceeding events (single cell aneuploidy) show
that the case has complex karyotype usually developing
some aneuploid cells. In contrary, in case of simple
karyotype this phenomenon can not be detected. Little is
known about the prognostic value of DNA ploidy (at
flow and image cytometry level). El-Naggar et al.a n d
Lopes et al. found that ploidy status (aneuploidy) corre-
lated significantly with reduced patient survival in SS
[19,20]. However, the vast majority of SSs are diploid and
these diploid tumors are aggressive in several cases.
Furthermore, our previous results did not find ploidy
(diploid, aneuploid group) as an independent prognostic
factor [8]. Conversely, promising results were published
about the SS cases with complex karyotype that show an
inverse correlation with prognosis.
We would like to find a feasible method to detect possi-
ble aberrations which may reflect the cytogenetic altera-
tions within the diploid group. The detection of single cell
aneuploidy in parallel to the diploid stemline was in corre-
lation with the complex caryotype. Single cell aneuploidy
is a well known phenomenon and its detection is applied
e.g. in the diagnostics of cervical dysplasia-carcinoma.
[21,22]. Although the 3 groups (simple diploid - complex
diploid - aneuploid)were significantly different, we cannot
be completely sure in the unequivocally good prognoses of
the simple diploid cases (12 out of 27 cases developed
metastasis), still the tendency is unambiguous. By detect-
ing single cell aneuploidy in the diploid group, we know
that it means a complex karyotype at cytogenetic level and
so there is a simple, inexpensive and fast tool available to
provide important complementary data.
There are numerous prognostic factors in case of SSs to
consider and some of them are still a matter of debate e.g.
type of translocation (SSX1 or SSX2) and the histology
type (monophasic or biphasic) [2,4,7,9,11,20,23]. The
clearest prognostic factor is the size of the tumor (above
or below 5 cm) but unfortunately in most of the cases
(except the childhood SSs), at the time of diagnosis the
tumor is larger than 5 cm as has happened in all of our
examined cases.
In summary, measurement of DNA ploidy and separa-
tion of the diploid group based on single cell aneuploidy
might provide us useful complementary data which
reflects well the cytogenetic results and accordingly it
may help the oncologists to select the appropriate
therapy.
Conclusions
Although synovial sarcoma is the 3rd most commonly
occurring mesenchymal tumor in young adults, usually
with a highly aggressive clinical course, remarkable dif-
ferences can be seen in the clinical outcome. We found
a feasible method to detect possible aberrations which
may reflect the cytogenetic alterations within the diploid
group. The detection of single cell aneuploidy in parallel
to the diploid stemline might provide us useful comple-
mentary data which reflects well the cytogenetic results
Table 3 Use of Fisher’s exact test whether the simple,
complex diploid and aneuploid groups can be separated
Histogram M R N Total
Simple diploid 12 7 8 27
Complex diploid 5 2 2 9
Aneuploid 10 0 0 10
Total 27 9 10 46
The three-rows by three-columns contingency table should be used if the
total size of the data set is no greater than N = 90 and/or any cell value is
less than 5.
p = 0.040127
Abbreviations: M, metastasis; R, recurrence; N, neither recurrence nor
metastasis
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appropriate therapy.
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